Vir Biotechnology, Inc. (VIR) stock
VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3036% below fair value
$8.39−0.48 (-5.41%)
Close on Nov 20, 2026Market cap $1.42BP/E –Yield –
Vir Biotechnology gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Vir Biotechnology's gross profit for the twelve months ending Jun 30, 2025 was $18.26M, down 76.6% year over year. For fiscal 2025 it was $68.53M, down 6.6% from the year before. The highest annual figure on record is $1.47B in fiscal 2022.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $68.53M | -6.6% |
| FY2024 | Dec 31, 2024 | $73.36M | -12.1% |
| FY2023 | Dec 31, 2023 | $83.42M | -94.3% |
| FY2022 | Dec 31, 2022 | $1.47B | +42.7% |
| FY2021 | Dec 31, 2021 | $1.03B | +1248.1% |
| FY2020 | Dec 31, 2020 | $76.37M | +843.9% |
| FY2019 | Dec 31, 2019 | $8.09M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $238.95M | +10155.2% |
| Q2 FY2025 | Jun 30, 2025 | $1.20M | -60.2% |
| Q1 FY2025 | Mar 31, 2025 | $3.03M | -94.6% |
| Q4 FY2024 | Dec 31, 2024 | $11.69M | -26.9% |
| Q3 FY2024 | Sep 30, 2024 | $2.33M | -10.4% |
| Q2 FY2024 | Jun 30, 2024 | $3.02M | -19.9% |
| Q1 FY2024 | Mar 31, 2024 | $56.32M | -7.8% |
| Q4 FY2023 | Dec 31, 2023 | $15.99M | -63.2% |
| Q3 FY2023 | Sep 30, 2023 | $2.60M | -99.3% |
| Q2 FY2023 | Jun 30, 2023 | $3.78M | – |
| Q1 FY2023 | Mar 31, 2023 | $61.05M | -94.7% |
| Q4 FY2022 | Dec 31, 2022 | $43.41M | -94.3% |
| Q3 FY2022 | Sep 30, 2022 | $352.30M | +267.8% |
| Q2 FY2022 | Jun 30, 2022 | -$68.55M | -139.0% |
| Q1 FY2022 | Mar 31, 2022 | $1.14B | +57709.2% |
| Q4 FY2021 | Dec 31, 2021 | $755.87M | +43491.1% |
| Q3 FY2021 | Sep 30, 2021 | $95.78M | +4867.8% |
| Q2 FY2021 | Jun 30, 2021 | $175.92M | +162.6% |
| Q1 FY2021 | Mar 31, 2021 | $1.98M | – |
| Q4 FY2020 | Dec 31, 2020 | $1.73M | – |
| Q3 FY2020 | Sep 30, 2020 | $1.93M | – |
| Q2 FY2020 | Jun 30, 2020 | $66.99M | – |
See a number that looks wrong?